---

Highlights of November 2019

1. Lupin sells Japanese arm Kyowa for US$300 Million.
2. Cadila Healthcare acquires remaining stake in 2 subsidiaries for US$250,000.
3. Sun Pharma inks licensing pact with AstraZeneca to introduce products in China.
4. Samsung Biologics and Ichnos Sciences (a spin-off of Glenmark) Announce Agreement for Manufacture of ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis.
5. Dr. Reddy’s Labs taps contract manufacturer to access Chinese markets.
6. Sarepta pays StrideBio US$48 Million for preclinical gene therapies.
7. Aurobindo Pharma to acquire certain biz assets of Profectus BioSciences.
8. Recipharm bolsters its inhalation and injectables manufacturing with US$650 Million deal for Consort Medical.
9. Merck to pay up to US$576 Million for Calporta Therapeutics.
10. Novo Nordisk taps Dicerna's RNAi tech in US$225M metabolic, liver disease deal.
11. Allergan pays Exicure US$25 Million to discover nucleic acid hair loss drugs.

Updates at Aagami

• Aagami completed a fruitful BIO-Europe 2019 in Hamburg with more than 40 one-on-one strategic meetings with CxOs of world-wide Pharma, Biotech and Medical Technology companies.
• Aagami CEO Dinesh Jain will be in India all of Dec 2019 to represent various global clients.
• Aagami to attend JP Morgan Healthcare Conference and Biotech Showcase [BTS] (January 2020). Meetings calendar is now open, please contact us at godwyn@aagami.com, akshay@aagami.com, or send us a meeting request on the BTS partnering system.